Share on StockTwits

Medivation (NASDAQ:MDVN) Insider Lynn Seely sold 20,000 shares of the stock on the open market in a transaction that occurred on Wednesday, August 13th. The stock was sold at an average price of $83.62, for a total transaction of $1,672,400.00. Following the transaction, the insider now directly owns 59,022 shares in the company, valued at approximately $4,935,420. The transaction was disclosed in a filing with the SEC, which is available at this link.

MDVN has been the subject of a number of recent research reports. Analysts at Aegis raised their price target on shares of Medivation from $125.00 to $130.00 in a research note on Friday, August 8th. Separately, analysts at Leerink Swann raised their price target on shares of Medivation from $104.00 to $107.00 in a research note on Friday, August 8th. Finally, analysts at Keefe, Bruyette & Woods reiterated an “outperform” rating on shares of Medivation in a research note on Friday, August 8th. They now have a $107.00 price target on the stock, up previously from $104.00. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and eight have issued a buy rating to the stock. Medivation has a consensus rating of “Buy” and a consensus price target of $96.47.

Shares of Medivation (NASDAQ:MDVN) traded up 1.68% on Thursday, hitting $84.22. The stock had a trading volume of 1,147,639 shares. Medivation has a one year low of $48.15 and a one year high of $88.20. The stock’s 50-day moving average is $76.67 and its 200-day moving average is $71.75. The company has a market cap of $6.467 billion and a P/E ratio of 266.33.

Medivation (NASDAQ:MDVN) last released its earnings data on Thursday, August 7th. The company reported $0.60 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.24 by $0.36. The company had revenue of $148.09 million for the quarter, compared to the consensus estimate of $126.46 million. During the same quarter last year, the company posted ($0.07) earnings per share. Medivation’s revenue was up 111.1% compared to the same quarter last year. On average, analysts predict that Medivation will post $2.38 earnings per share for the current fiscal year.

Medivation, Inc is a biopharmaceutical company focused on the development and commercialization of novel therapies.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.